Eli Lilly Breaks Ground on $6.5 Billion Houston Plant for Foundayo
CEO Dave Ricks breaks ground on a facility to produce active ingredients for the oral weight-loss drug, as adoption of GLP-1 therapies expands under Medicare.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
2 publishers have covered this in 8 articles since 21 Sept 2026. CNBC published first, on 21 September at 17:14 UTC; Quartz followed 16 min later. The most recent article, from Quartz, appeared on 22 September at 13:10 UTC.
Outlets reporting it: CNBC (major outlet), Quartz.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- CNBCEli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- QuartzLilly's Foundayo pill wins over a third of new patients, CEO says
- QuartzLillys Foundayo-Pille gewinnt mehr als ein Drittel neuer Patienten, sagt der CEO.
- CNBCEli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
- QuartzEli Lilly broke ground on a $6.5 billion Houston plant for its oral weight loss pill
- QuartzEli Lilly begann mit dem Bau einer 6,5 Milliarden Dollar teuren Anlage in Houston für seine orale Gewichtsverlustpille.
- QuartzEli Lilly is capturing 70% of new Medicare patients on weight-loss drugs, CEO says
- QuartzEli Lilly erfasst 70 % der neuen Medicare-Patienten bei Medikamenten zur Gewichtsreduktion, sagt der CEO.
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs CNBC ·
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production CNBC ·
- Eli Lilly erfasst 70 % der neuen Medicare-Patienten bei Medikamenten zur Gewichtsreduktion, sagt der CEO. Quartz
- Eli Lilly is capturing 70% of new Medicare patients on weight-loss drugs, CEO says Quartz
- Eli Lilly begann mit dem Bau einer 6,5 Milliarden Dollar teuren Anlage in Houston für seine orale Gewichtsverlustpille. Quartz
- Eli Lilly broke ground on a $6.5 billion Houston plant for its oral weight loss pill Quartz
- Lilly's Foundayo pill wins over a third of new patients, CEO says Quartz
- Lillys Foundayo-Pille gewinnt mehr als ein Drittel neuer Patienten, sagt der CEO. Quartz
In this story
- Eli Lilly
- Dave Ricks
- Houston